Connect with us

3 Gene Therapy Stocks

3 Gene Therapy Stocks

Published

on

  • Biotech stocks and the broader healthcare sector remain under pressure.
  • Promising opportunities exist in the small-cap and mid-cap segments.
  • Gene therapy remains the emerging scientific frontier in biotech.
  • 3 promising small-cap gene therapy stocks for a biotech portfolio.

Biotech Pulse

PrudentBiotech.com ~  Biotech pulse

The Nasdaq Biotech (IBB) and the S&P Biotech (XBI) indexes have struggled since March as the broader healthcare sector (XLV) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader market indexes, the Nasdaq Composite (QQQ), and the S&P 500 (SPY), set new highs, prior to the recent pullback.

The trade friction has a more restrained immediate impact on the biotechs and affects the broader biopharma sector mostly in the area of patent protection and market exclusivity terms that are negotiated. But the flight from risk, as expectations of an imminent trade resolution were derailed, hurt the speculative sector, like the biotechs, more sharply.

The healthcare overhaul and uncertainty will remain an ongoing theme until the elections, leading to higher sector volatility and restrained gains, as highlighted in the article 2019 Outlook: Biotech Bonanza: 2019 Outlook On An Uphill Battle. Nonetheless, there will be attractive opportunities, particularly in midcap and smallcap segments, to outperform the biotech indexes. One segment of biotechs that is attractive for its emerging potential is discussed below.

Gene Therapy

PrudentBiotech.com ~ GENE

Source: BioSpace.com

Gene therapy is a generational scientific advancement with the potential to make a growing and gigantic impact on healthcare. 

Genes are part of the DNA that provides the blueprint instructions to the cells for making proteins. A mutation or a defect in the gene can prevent the cells from creating an accurate expression of the protein or a diminished ability to do so. Gene therapy is the science of altering DNA to restore normal protein expression by the cells or even silence proteins that may cause debilitating diseases.

There has been a surge of interest in gene therapy as key milestones are being achieved, particularly in rare diseases, and the scientific advances are pushing the frontiers of genomic medicine. Significant progress has been made in improving the understanding of using different delivery vehicles or vectors to safely deliver the therapeutic DNA altering payload. CRISPR, which makes addition and deletion edits directly to the DNA strand, is a popular editing tool in gene therapy. Another approach to correcting gene mutation that is gaining popularity is the use of viral vectors to deliver the therapeutic payload. Any viral vector needs to be non-pathogenic in order to minimize any immune response so that the vector particle, and the embedded payload, is not destroyed by the antibodies.

Two types of viral vector platforms being used are the Adeno-Associated Virus (AAV) for the in vivo gene therapy and the Lentivirus from stem cells for ex vivo gene therapy. Using particles of AAV, which is not known to cause disease and typically has a mild immune response, is garnering a lot of interest as a virus vector in gene therapy for many targeted diseases. But challenges exist particularly around AAV-antibodies which can pre-exist in patients. Research has advanced to a point where variants of AAVs are being used to improve the immunogenicity profile, which means minimal immune reaction when a viral vector is introduced in the body. 

There are a growing number of gene therapy companies with a wide range of market caps. A few of them include Editas (EDIT), Crispr (CRSP), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), Homology Medicines (FIXX), Sarepta Therapeutics (SRPT), Bluebird (BLUE), Regenxbio (RGNX), PTC Therapeutics (PTCT), Meiragtx (MGTX), and Intella Therapeutics (NTLA).

Investor interest in gene therapy companies has also been spurred by acquisition activity at sizable premiums – Spark Therapeutics was acquired by Roche (RHHBY) earlier this year for an over 100% premium, and Avexis was acquired by Novartis (NVS) early in 2018 at an over 70% premium.

Here is a look at 3 promising small cap gene therapy companies. 

Uniqure (QURE)

The company is a platform driven gene therapeutic company. A robust technology platform allows multiple shots at the goal and thus reduces a risk profile compared to single-product biotech. 

Uniqure has a modular gene therapy platform, which allows it to leverage the core technology for a variety of targeted therapies using its AAV vector delivery system. The Company uses an engineered virus variant called AAV5, which its research has shown to have a favorable immunogenicity profile even in the patient population with pre-existing AAV neutralizing antibodies. Uniqure has exclusive worldwide rights to the AAV 5 variant used in therapies delivered to the brain or liver and uses its own manufacturing lab and a proprietary process to produce its AAV-based gene therapies. 

Uniqure is working on a few liver and neurological targets. It’s most advanced therapeutic programs are in hemophilia, a blood clotting gene disorder, while other programs are in preclinicals or Phase I.

PrudentBiotech.com ~ Uniqure (QURE)

Uniqure Product PipelineSource: Uniqure (click for a clearer image)

Last week, the Company announced further data on its promising and clinically most advanced program, AMT-061, for Hemophilia B and the results were strikingly promising. The Hemophilia B disorder is caused by a missing or defective copy of Factor IX or FIX, a blood clotting protein, and is both hereditary as well as a spontaneous mutation with no family history. In the Phase 1b study of AMT-061, an investigational AAV5-based gene therapy for the treatment of patients with severe and moderately severe hemophilia B, all the 3 patients administered showed sustained FIX levels of the protein and two of the patients recording readings within 50% of normal range at the 6-month interval after dosing. Very important, there were no safety issues with regards to tolerability and no patient required immunosuppression relating to the therapy, this despite all 3 patients showings low levels of pre-existing neutralizing AAV5 antibodies. The sustainability of the improvement after 6 months and the safety profile with no adverse immunological reaction was striking.

Last year, Uniqure began its ‘HOPE-B’ Phase 3 trial of AMT-061 for adults with moderately severe or severe hemophilia. The trial will evaluate the efficacy and safety of AMT-061. The enrolled patients will be first observed for six-months on their current standard of care, and thereafter receive a single dosage of AMT-061. The primary outcome measure is the assessment of Factor IX activity 26 weeks after the dosing. The trial is expected to be fully enrolled, with about 50 patients, later in 2019. Earlier, in February 2019, the Company announced the treatment of the first patient in the trial. The 6-month period after dosing should end around August 2019, and one would anticipate the company providing some information thereafter. Investor focus will remain on the results of the AMT-061 drug Hemophilia B and whether the program can advance towards commercialization.

As of the end of the March quarter, the company had $210 million in cash and equivalents and expects this liquidity to fund operations into 2021.

Voyager Therapeutics (VYGR)

Voyager is a clinical-stage gene therapy company focused on neurological diseases. The Company uses AAV vectors in developing its gene therapies and has the production ability to engineer these vectors at scale with the appropriate therapeutic payloads. Voyage Therapeutics has a core AAV-driven platform to develop vectorized antibodies for various diseases.  

The Company’s product pipeline is targeting some of the hardest neurological diseases to resolve, which also include Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s disease, Alzheimer’s disease, and other diseases related to defective or excess aggregation of tau proteins in the brain.

PrudentBiotech.com ~ Voyager Therapeutics (VYGR)

Voyager Therapeutics Product PipelineSource: Voyager Therapeutics (click for a clearer image)

In March 2019, the Company began a collaboration with Neurocrine Biosciences (NBIX) for gene therapy drug development targeting Parkinson and Ataxia. The announcement of Phase 1b interim trial data in March from the administration of VY-AADC, demonstrated safety, tolerability, and improvement in clinical measures. The other programs are in preclinical stages and have garnered significant collaboration interest. The company is collaborating with Abbvie (ABBV) on Alzheimer and other neurodegenerative diseases, and with Sanofi-Genzyme (SNY) on Huntington Disease and Ataxia. There are a variety of upfront and milestone payments associated with the collaborations.

Investor focus will remain on continued progress in its various programs, including long-term data from the Phase 1b trial for VY-AADC. Voyager has also initiated a Phase 2 trial referred to as RESTORE 1, for patients with Parkinson’s disease for at least 4 years. The primary endpoints will be measured after 12 months. The trial is expected to fully enroll by mid-2020.

The Company had a cash position of ~$360 million at the end of the March 2019 quarter and expects to have sufficient liquidity to fund operations until mid-2022.

Audentes Therapeutics (BOLD)

Audentes is a gene therapy company leveraging its AAV-based vector technology platform to focus on rare neuromuscular diseases. The company has its own manufacturing expertise to engineer the proprietary AAV vectors to deliver the therapeutic payloads. 

The Company’s product pipeline is targeting Myopathy, Pompe, and Duchenne Muscular Dystrophy (DMD). 

PrudentBiotech.com ~ Audentes Therapeutics (BOLD)

Audentes Therapeutics Product PipelineSource: Audentes Therapeutics presentation (click for a clearer image)

The most progressed program is for the candidate AT132 in Phase 1/2 to treat X-linked Myotubular Myopathy (XLMTM). This is a life-threatening disease characterized by extreme muscle weakness and a high mortality rate of 75% by age 10 for those who survive past infancy. It is caused by mutations in the MTM1 gene that leads to dysfunctional production of myotubularin protein. The AT132, which is a novel AAV8 vector with a functional copy of the MTM1 gene, has received a Fast Track and Orphan designation from the FDA. The ASPIRO Phase 1/2 study is evaluating the safety and efficacy of AT132. 

Earlier in May, new positive data was released from the ASPIRO study demonstrating a good tolerability and safety profile, along with a sustained reduction in ventilator dependence for the 6-patient cohort. The company is working on gene therapies for some complex neuromuscular diseases and the progress of its products for Myopathy (AT132), Pompe (AT845), and Duchenne Muscular Dystrophy (AT702) will be watched carefully by investors. On AT132, Audentes expects to select an optimal dose during this quarter, with the next clinical data presentation in October. In the case of AT845 for Pompe disease, the Company expects to file an IND in the third quarter of 2019, and for DMD, an IND filing is expected in 2020.

The Company had a cash position of $375 million at the end of the March 2019 quarter and expects this liquidity to provide sufficient runway into 2021.

PrudentBiotech.com ~ Virus

Source: iphoto

Conclusion

Gene therapy stocks are pushing a new frontier of science. Interest has continued to rise due to the enticing promising of potentially curing a spectrum of diseases and conditions in a more targeted, effective, and durable manner. New ideas in gene therapy are finding ready and eager financing and the ambitions are growing. The most recent announcement was the launch of a gene therapy effort targeting cardiovascular health,  by start-up Verve Therapeutics and backed by Google (GOOG) parent Alphabet.

However, as investors realize, any generational advance, similar to a paradigm change, in tackling diseases is not going to be without major setbacks. Such has been the case in gene therapy as well. It is better to pursue a portfolio approach in this dynamic segment and the above three companies, Uniqure, Voyager and Audentes, are some of the speculative promising prospects in gene therapy. These companies have a gene therapy development platform, are targeting multiple indications, and have achieved some important initial successes. And they are just a few of a growing pool of gene therapy companies targeting complex diseases with their high potential and innovative gene therapies. 

Some other promising biotech companies, which may be now or in the past be part of the Prudent Biotech model portfolio or the Graycell Small Cap portfolio, include Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Amarin (AMRN), GW Pharmaceuticals (GWPH), Denali Therapeutics (DNLI), Acadia Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), Array BioPharma (ARRY), Ascendis Pharma (ASND), Pacira Pharmaceuticals (PCRX), China Biologics (CBPO), Uniqure (QURE), Moderna (MRNA), PTC Therapeutics (PTCT), Mirati Therapeutics (MRTX), Ra Pharmaceuticals (RARX), Bluebird Bio (BLUE), Allogene Therapeutics (ALLO), Portola Pharmaceuticals (PTLA), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), Medicine Company (MDCO), Ziopharm Oncology (ZIOP), Coherus Biosciences (CHRS), and Arrowhead Pharmaceuticals (ARWR). This is just a short list.

As always, use a portfolio approach to invest, particularly with biotech stocks, to overcome the inevitable errors.

The article was first published on Seeking Alpha.

The post 3 Gene Therapy Stocks appeared first on Prudent Biotech.

Read More

Continue Reading

Government

Are Voters Recoiling Against Disorder?

Are Voters Recoiling Against Disorder?

Authored by Michael Barone via The Epoch Times (emphasis ours),

The headlines coming out of the Super…

Published

on

Are Voters Recoiling Against Disorder?

Authored by Michael Barone via The Epoch Times (emphasis ours),

The headlines coming out of the Super Tuesday primaries have got it right. Barring cataclysmic changes, Donald Trump and Joe Biden will be the Republican and Democratic nominees for president in 2024.

(Left) President Joe Biden delivers remarks on canceling student debt at Culver City Julian Dixon Library in Culver City, Calif., on Feb. 21, 2024. (Right) Republican presidential candidate and former U.S. President Donald Trump stands on stage during a campaign event at Big League Dreams Las Vegas in Las Vegas, Nev., on Jan. 27, 2024. (Mario Tama/Getty Images; David Becker/Getty Images)

With Nikki Haley’s withdrawal, there will be no more significantly contested primaries or caucuses—the earliest both parties’ races have been over since something like the current primary-dominated system was put in place in 1972.

The primary results have spotlighted some of both nominees’ weaknesses.

Donald Trump lost high-income, high-educated constituencies, including the entire metro area—aka the Swamp. Many but by no means all Haley votes there were cast by Biden Democrats. Mr. Trump can’t afford to lose too many of the others in target states like Pennsylvania and Michigan.

Majorities and large minorities of voters in overwhelmingly Latino counties in Texas’s Rio Grande Valley and some in Houston voted against Joe Biden, and even more against Senate nominee Rep. Colin Allred (D-Texas).

Returns from Hispanic precincts in New Hampshire and Massachusetts show the same thing. Mr. Biden can’t afford to lose too many Latino votes in target states like Arizona and Georgia.

When Mr. Trump rode down that escalator in 2015, commentators assumed he’d repel Latinos. Instead, Latino voters nationally, and especially the closest eyewitnesses of Biden’s open-border policy, have been trending heavily Republican.

High-income liberal Democrats may sport lawn signs proclaiming, “In this house, we believe ... no human is illegal.” The logical consequence of that belief is an open border. But modest-income folks in border counties know that flows of illegal immigrants result in disorder, disease, and crime.

There is plenty of impatience with increased disorder in election returns below the presidential level. Consider Los Angeles County, America’s largest county, with nearly 10 million people, more people than 40 of the 50 states. It voted 71 percent for Mr. Biden in 2020.

Current returns show county District Attorney George Gascon winning only 21 percent of the vote in the nonpartisan primary. He’ll apparently face Republican Nathan Hochman, a critic of his liberal policies, in November.

Gascon, elected after the May 2020 death of counterfeit-passing suspect George Floyd in Minneapolis, is one of many county prosecutors supported by billionaire George Soros. His policies include not charging juveniles as adults, not seeking higher penalties for gang membership or use of firearms, and bringing fewer misdemeanor cases.

The predictable result has been increased car thefts, burglaries, and personal robberies. Some 120 assistant district attorneys have left the office, and there’s a backlog of 10,000 unprosecuted cases.

More than a dozen other Soros-backed and similarly liberal prosecutors have faced strong opposition or have left office.

St. Louis prosecutor Kim Gardner resigned last May amid lawsuits seeking her removal, Milwaukee’s John Chisholm retired in January, and Baltimore’s Marilyn Mosby was defeated in July 2022 and convicted of perjury in September 2023. Last November, Loudoun County, Virginia, voters (62 percent Biden) ousted liberal Buta Biberaj, who declined to prosecute a transgender student for assault, and in June 2022 voters in San Francisco (85 percent Biden) recalled famed radical Chesa Boudin.

Similarly, this Tuesday, voters in San Francisco passed ballot measures strengthening police powers and requiring treatment of drug-addicted welfare recipients.

In retrospect, it appears the Floyd video, appearing after three months of COVID-19 confinement, sparked a frenzied, even crazed reaction, especially among the highly educated and articulate. One fatal incident was seen as proof that America’s “systemic racism” was worse than ever and that police forces should be defunded and perhaps abolished.

2020 was “the year America went crazy,” I wrote in January 2021, a year in which police funding was actually cut by Democrats in New York, Los Angeles, San Francisco, Seattle, and Denver. A year in which young New York Times (NYT) staffers claimed they were endangered by the publication of Sen. Tom Cotton’s (R-Ark.) opinion article advocating calling in military forces if necessary to stop rioting, as had been done in Detroit in 1967 and Los Angeles in 1992. A craven NYT publisher even fired the editorial page editor for running the article.

Evidence of visible and tangible discontent with increasing violence and its consequences—barren and locked shelves in Manhattan chain drugstores, skyrocketing carjackings in Washington, D.C.—is as unmistakable in polls and election results as it is in daily life in large metropolitan areas. Maybe 2024 will turn out to be the year even liberal America stopped acting crazy.

Chaos and disorder work against incumbents, as they did in 1968 when Democrats saw their party’s popular vote fall from 61 percent to 43 percent.

Views expressed in this article are opinions of the author and do not necessarily reflect the views of The Epoch Times or ZeroHedge.

Tyler Durden Sat, 03/09/2024 - 23:20

Read More

Continue Reading

Government

Veterans Affairs Kept COVID-19 Vaccine Mandate In Place Without Evidence

Veterans Affairs Kept COVID-19 Vaccine Mandate In Place Without Evidence

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

The…

Published

on

Veterans Affairs Kept COVID-19 Vaccine Mandate In Place Without Evidence

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

The U.S. Department of Veterans Affairs (VA) reviewed no data when deciding in 2023 to keep its COVID-19 vaccine mandate in place.

Doses of a COVID-19 vaccine in Washington in a file image. (Jacquelyn Martin/Pool/AFP via Getty Images)

VA Secretary Denis McDonough said on May 1, 2023, that the end of many other federal mandates “will not impact current policies at the Department of Veterans Affairs.”

He said the mandate was remaining for VA health care personnel “to ensure the safety of veterans and our colleagues.”

Mr. McDonough did not cite any studies or other data. A VA spokesperson declined to provide any data that was reviewed when deciding not to rescind the mandate. The Epoch Times submitted a Freedom of Information Act for “all documents outlining which data was relied upon when establishing the mandate when deciding to keep the mandate in place.”

The agency searched for such data and did not find any.

The VA does not even attempt to justify its policies with science, because it can’t,” Leslie Manookian, president and founder of the Health Freedom Defense Fund, told The Epoch Times.

“The VA just trusts that the process and cost of challenging its unfounded policies is so onerous, most people are dissuaded from even trying,” she added.

The VA’s mandate remains in place to this day.

The VA’s website claims that vaccines “help protect you from getting severe illness” and “offer good protection against most COVID-19 variants,” pointing in part to observational data from the U.S. Centers for Disease Control and Prevention (CDC) that estimate the vaccines provide poor protection against symptomatic infection and transient shielding against hospitalization.

There have also been increasing concerns among outside scientists about confirmed side effects like heart inflammation—the VA hid a safety signal it detected for the inflammation—and possible side effects such as tinnitus, which shift the benefit-risk calculus.

President Joe Biden imposed a slate of COVID-19 vaccine mandates in 2021. The VA was the first federal agency to implement a mandate.

President Biden rescinded the mandates in May 2023, citing a drop in COVID-19 cases and hospitalizations. His administration maintains the choice to require vaccines was the right one and saved lives.

“Our administration’s vaccination requirements helped ensure the safety of workers in critical workforces including those in the healthcare and education sectors, protecting themselves and the populations they serve, and strengthening their ability to provide services without disruptions to operations,” the White House said.

Some experts said requiring vaccination meant many younger people were forced to get a vaccine despite the risks potentially outweighing the benefits, leaving fewer doses for older adults.

By mandating the vaccines to younger people and those with natural immunity from having had COVID, older people in the U.S. and other countries did not have access to them, and many people might have died because of that,” Martin Kulldorff, a professor of medicine on leave from Harvard Medical School, told The Epoch Times previously.

The VA was one of just a handful of agencies to keep its mandate in place following the removal of many federal mandates.

“At this time, the vaccine requirement will remain in effect for VA health care personnel, including VA psychologists, pharmacists, social workers, nursing assistants, physical therapists, respiratory therapists, peer specialists, medical support assistants, engineers, housekeepers, and other clinical, administrative, and infrastructure support employees,” Mr. McDonough wrote to VA employees at the time.

This also includes VA volunteers and contractors. Effectively, this means that any Veterans Health Administration (VHA) employee, volunteer, or contractor who works in VHA facilities, visits VHA facilities, or provides direct care to those we serve will still be subject to the vaccine requirement at this time,” he said. “We continue to monitor and discuss this requirement, and we will provide more information about the vaccination requirements for VA health care employees soon. As always, we will process requests for vaccination exceptions in accordance with applicable laws, regulations, and policies.”

The version of the shots cleared in the fall of 2022, and available through the fall of 2023, did not have any clinical trial data supporting them.

A new version was approved in the fall of 2023 because there were indications that the shots not only offered temporary protection but also that the level of protection was lower than what was observed during earlier stages of the pandemic.

Ms. Manookian, whose group has challenged several of the federal mandates, said that the mandate “illustrates the dangers of the administrative state and how these federal agencies have become a law unto themselves.”

Tyler Durden Sat, 03/09/2024 - 22:10

Read More

Continue Reading

Spread & Containment

The Coming Of The Police State In America

The Coming Of The Police State In America

Authored by Jeffrey Tucker via The Epoch Times,

The National Guard and the State Police are now…

Published

on

The Coming Of The Police State In America

Authored by Jeffrey Tucker via The Epoch Times,

The National Guard and the State Police are now patrolling the New York City subway system in an attempt to do something about the explosion of crime. As part of this, there are bag checks and new surveillance of all passengers. No legislation, no debate, just an edict from the mayor.

Many citizens who rely on this system for transportation might welcome this. It’s a city of strict gun control, and no one knows for sure if they have the right to defend themselves. Merchants have been harassed and even arrested for trying to stop looting and pillaging in their own shops.

The message has been sent: Only the police can do this job. Whether they do it or not is another matter.

Things on the subway system have gotten crazy. If you know it well, you can manage to travel safely, but visitors to the city who take the wrong train at the wrong time are taking grave risks.

In actual fact, it’s guaranteed that this will only end in confiscating knives and other things that people carry in order to protect themselves while leaving the actual criminals even more free to prey on citizens.

The law-abiding will suffer and the criminals will grow more numerous. It will not end well.

When you step back from the details, what we have is the dawning of a genuine police state in the United States. It only starts in New York City. Where is the Guard going to be deployed next? Anywhere is possible.

If the crime is bad enough, citizens will welcome it. It must have been this way in most times and places that when the police state arrives, the people cheer.

We will all have our own stories of how this came to be. Some might begin with the passage of the Patriot Act and the establishment of the Department of Homeland Security in 2001. Some will focus on gun control and the taking away of citizens’ rights to defend themselves.

My own version of events is closer in time. It began four years ago this month with lockdowns. That’s what shattered the capacity of civil society to function in the United States. Everything that has happened since follows like one domino tumbling after another.

It goes like this:

1) lockdown,

2) loss of moral compass and spreading of loneliness and nihilism,

3) rioting resulting from citizen frustration, 4) police absent because of ideological hectoring,

5) a rise in uncontrolled immigration/refugees,

6) an epidemic of ill health from substance abuse and otherwise,

7) businesses flee the city

8) cities fall into decay, and that results in

9) more surveillance and police state.

The 10th stage is the sacking of liberty and civilization itself.

It doesn’t fall out this way at every point in history, but this seems like a solid outline of what happened in this case. Four years is a very short period of time to see all of this unfold. But it is a fact that New York City was more-or-less civilized only four years ago. No one could have predicted that it would come to this so quickly.

But once the lockdowns happened, all bets were off. Here we had a policy that most directly trampled on all freedoms that we had taken for granted. Schools, businesses, and churches were slammed shut, with various levels of enforcement. The entire workforce was divided between essential and nonessential, and there was widespread confusion about who precisely was in charge of designating and enforcing this.

It felt like martial law at the time, as if all normal civilian law had been displaced by something else. That something had to do with public health, but there was clearly more going on, because suddenly our social media posts were censored and we were being asked to do things that made no sense, such as mask up for a virus that evaded mask protection and walk in only one direction in grocery aisles.

Vast amounts of the white-collar workforce stayed home—and their kids, too—until it became too much to bear. The city became a ghost town. Most U.S. cities were the same.

As the months of disaster rolled on, the captives were let out of their houses for the summer in order to protest racism but no other reason. As a way of excusing this, the same public health authorities said that racism was a virus as bad as COVID-19, so therefore it was permitted.

The protests had turned to riots in many cities, and the police were being defunded and discouraged to do anything about the problem. Citizens watched in horror as downtowns burned and drug-crazed freaks took over whole sections of cities. It was like every standard of decency had been zapped out of an entire swath of the population.

Meanwhile, large checks were arriving in people’s bank accounts, defying every normal economic expectation. How could people not be working and get their bank accounts more flush with cash than ever? There was a new law that didn’t even require that people pay rent. How weird was that? Even student loans didn’t need to be paid.

By the fall, recess from lockdown was over and everyone was told to go home again. But this time they had a job to do: They were supposed to vote. Not at the polling places, because going there would only spread germs, or so the media said. When the voting results finally came in, it was the absentee ballots that swung the election in favor of the opposition party that actually wanted more lockdowns and eventually pushed vaccine mandates on the whole population.

The new party in control took note of the large population movements out of cities and states that they controlled. This would have a large effect on voting patterns in the future. But they had a plan. They would open the borders to millions of people in the guise of caring for refugees. These new warm bodies would become voters in time and certainly count on the census when it came time to reapportion political power.

Meanwhile, the native population had begun to swim in ill health from substance abuse, widespread depression, and demoralization, plus vaccine injury. This increased dependency on the very institutions that had caused the problem in the first place: the medical/scientific establishment.

The rise of crime drove the small businesses out of the city. They had barely survived the lockdowns, but they certainly could not survive the crime epidemic. This undermined the tax base of the city and allowed the criminals to take further control.

The same cities became sanctuaries for the waves of migrants sacking the country, and partisan mayors actually used tax dollars to house these invaders in high-end hotels in the name of having compassion for the stranger. Citizens were pushed out to make way for rampaging migrant hordes, as incredible as this seems.

But with that, of course, crime rose ever further, inciting citizen anger and providing a pretext to bring in the police state in the form of the National Guard, now tasked with cracking down on crime in the transportation system.

What’s the next step? It’s probably already here: mass surveillance and censorship, plus ever-expanding police power. This will be accompanied by further population movements, as those with the means to do so flee the city and even the country and leave it for everyone else to suffer.

As I tell the story, all of this seems inevitable. It is not. It could have been stopped at any point. A wise and prudent political leadership could have admitted the error from the beginning and called on the country to rediscover freedom, decency, and the difference between right and wrong. But ego and pride stopped that from happening, and we are left with the consequences.

The government grows ever bigger and civil society ever less capable of managing itself in large urban centers. Disaster is unfolding in real time, mitigated only by a rising stock market and a financial system that has yet to fall apart completely.

Are we at the middle stages of total collapse, or at the point where the population and people in leadership positions wise up and decide to put an end to the downward slide? It’s hard to know. But this much we do know: There is a growing pocket of resistance out there that is fed up and refuses to sit by and watch this great country be sacked and taken over by everything it was set up to prevent.

Tyler Durden Sat, 03/09/2024 - 16:20

Read More

Continue Reading

Trending